Why the study?
Does alogliptin prevent cardiac remodeling and apoptosis in non-diabetic pressure overload-induced heart failure?
Does alogliptin prevent cardiac remodeling and apoptosis in non-diabetic pressure overload-induced heart failure?
DPP4 inhibition with alogliptin mitigates pressure overload-induced heart failure remodeling and apoptosis by restoring GLP-1 levels and activating the EPAC1/Rap1 pathway independently of PKA.
DPP4i may preserve GLP-1 to limit remodeling in pressure overload; leaves open clinical translation in human HF.
No takes yet. Share an insight, caveat, or question.
Aoyama et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: